Professional Documents
Culture Documents
According to the report, the global hepatorenal syndrome treatment market was valued
at ~US$ 11 Bn in 2018 and is projected to expand at a CAGR of ~5% from 2019 to 2027. The
global hepatorenal syndrome treatment market is driven by an increase in the awareness
and acceptance of hepatorenal syndrome treatment.
The type 1 hepatorenal syndrome segment accounted for a major market share of the
hepatorenal syndrome treatment market in 2018. The segment is projected to expand at a
high CAGR during the forecast period, owing to the strong research & development focus of
manufacturers, besides the presence of a significant patient population.
Type 1 hepatorenal syndrome is a more severe form of hepatorenal syndrome. Type 1
hepatorenal syndrome is associated with overproduction of creatinine, resulting in rapid
kidney failure. Median survival time of patients with type 1 hepatorenal syndrome is two
weeks. Patients suffering from type 1 HRS die within 8 weeks to 10 weeks, unless a liver
transplant can be performed urgently.
The surgical treatment segment accounted for a major market share of the hepatorenal
syndrome treatment market in 2018. The dominance of the segment can be attributed to
the large patient population opting for surgical procedures due to kidney and liver failures.
Additionally, the high cost of kidney and liver surgeries is expected to drive the segment in
the global hepatorenal syndrome treatment market during the forecast period.
According to a study published in the Clinical Journal of American Society of Nephrology
(CJASN) 2017, around 40% of patients with stage 4 or 5 of chronic kidney disease receive
simultaneous liver-kidney transplants (SLKs)
Increase in the demand for the surgical treatment of hepatorenal syndrome treatment
is expected to boost the growth of the segment in the global hepatorenal syndrome
treatment market.
North America accounted for the largest market share of ~37% of the global
hepatorenal syndrome treatment market in 2018. This can be attributed to the large patient
population, increased disease awareness among people in the region, and measures
adopted by them for the treatment of diseases. Additionally, the launch of new pipeline
drug – Terlipressin - in the region, is expected to drive the hepatorenal syndrome treatment
market in North America during the forecast period.
Favorable reimbursement policies and huge insurance coverage for chronic kidney
disease patients, including kidney and liver transplants, is a major factor expected to fuel
the growth of the HRS treatment market in the next few years.
The report also provides the profiles of leading players operating in the global
hepatorenal syndrome treatment market. These include Cumberland Pharmaceuticals, Inc.,
Orphan Therapeutics, LLC, BioVie Inc., and Mallinckrodt Pharmaceuticals.
https://www.prnewswire.com/news-releases/players-in-pressure-relief-devices-market-lean-
on-launching-smart-therapeutic-beds-for-preventing-pressure-injuries-in-patients-market-
valuation-to-reach-us-4-54-bn-by-2030--finds-tmr-301349292.html
https://www.prnewswire.com/news-releases/urgent-care-centers-market-valuation-to-reach-
us-35-4-bn-by-2027-due-to-increased-access-to-healthcare-low-cost-of-treatment-finds-a-tmr-
study-301355857.html
https://www.prnewswire.com/news-releases/rise-in-prevalence-of-dry-eye-disease-due-to-
ageing-use-of-computers-to-drive-dry-eye-disease-treatment-market-says-tmr-301360562.html
About Us
Each TMR Syndicated Research report covers a different sector - such as pharmaceuticals,
chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and
technology. These reports provide in-depth analysis and deep segmentation to possible micro
levels. With wider scope and stratified research methodology, our syndicated reports thrive to
provide clients to serve their overall research requirement.
Contact
Albany, NY 12207
Tel: +1-518-618-1030
Website: https://www.transparencymarketresearch.com/